VI-60
VI-60 is a dual, orally active inhibitor of cPLA2 and COX-2, which reveals an anti-inflammtory efficacy through the inhibition of p38 MAPK/cPLA2/COX-2/PGE2 pathway.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 3050874-42-2
- Formule: C37H43F3O3
- Masse moléculaire:592.73
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Voir tous les produits spécifiques à Isoform Phospholipase
More
Activité biologique
|
COX-2 |
cPLA2 |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| RAW264.7 | IC50 |
3.85 μM
Compound: VI-60
|
Antiinflammatory activity in LPS-induced mouse RAW264.7 cells assessed as inhibition of NO production pretreated for 1 hr followed by LPS stimulation and measured after 24 hrs by griess reagent based assay
Antiinflammatory activity in LPS-induced mouse RAW264.7 cells assessed as inhibition of NO production pretreated for 1 hr followed by LPS stimulation and measured after 24 hrs by griess reagent based assay
|
[PMID: 38286094] |
VI-60 (10 μΜ, 24-48 h) inhibits the LPS-induced inflammatory mediators NO (IC50 is 3.85 μM) and PGE2 production without significant cytotoxicity in RAW264.7 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:RAW264.7
-
Concentration:30 μΜ
-
Incubation Time:24-48 h
-
Result:Exhibite cell viability of nearly 100%, in compare to the verhicle group.
-
Cell Line:RAW264.7
-
Concentration:30 μΜ, 2.5-10 μM
-
Incubation Time:30 μM for 2 h, 2.5-10 μM for 1 h
-
Result:Downregulated the phosphor-p38-MAPK, cPLA2 and COX2, stabilized the cPLA2 and COX2 proteins when heated.
VI-60 (20 mg/kg, p.o., everyday) regulates the balance between Th17 and Tregs and reduces IL-17 expression through inhibition of the p38 MAPK/cPLA2/COX-2/PGE2 pathway[1].
VI-60 exhibits a low ulcerative potential (50 mg/kg), no hepatotoxicity or nephrotoxicity (20 mg/kg, p.o.) in Wistar rats .
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Adjuvant-induced arthritis in Lewis rats[1]
-
Dosage:20 mg/kg
-
Administration:p.o., every 24 h or 48 h for 20 days
-
Result:Inhibited the weight loss and the edema of paws, increased the mechanical withdrawal threshold (MWT), decreased the spleen weights.
-
Animal Model:Male mistar rats[1]
-
Dosage:20 mg/kg
-
Administration:p.o., for 3 days
-
Result:Revealed identical indexes of glutamic pyruvic transaminase (GPT), glutamic oxalacetic transaminase (GOT), and blood urea nitrogen (BUN) as of normal rats.
Chemical Information
-
CAS No. 3050874-42-2
-
Masse moléculaire 592.73
-
Formule C37H43F3O3
-
SMILES
CCCCC/C=C\C/C=C\C/C=C\C/C=C\CC/C=C(C(F)(F)F)/OC(C(C)C1=CC=C(C(C2=CC=CC=C2)=O)C=C1)=O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
VI-60 Related Classifications
HY-162228 Related Classifications
Powered by Bioz